Affordable Access

deepdyve-link
Publisher Website

Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.

Authors
  • Dosne, Anne-Gaelle1
  • Valade, Elodie1
  • Stuyckens, Kim1
  • Li, Lilian Y2
  • Ouellet, Daniele2
  • Perez-Ruixo, Juan Jose1
  • 1 Global Clinical Pharmacology, Janssen Research & Development, Beerse, Belgium. , (Belgium)
  • 2 Global Clinical Pharmacology, Janssen Research & Development, Springhouse, Pennsylvania, USA.
Type
Published Article
Journal
Journal of clinical pharmacology
Publication Date
Apr 01, 2020
Volume
60
Issue
4
Pages
515–527
Identifiers
DOI: 10.1002/jcph.1547
PMID: 31742712
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

A population pharmacokinetic (PK) model was developed using data pooled from 6 clinical studies (3 in healthy volunteers and 3 in cancer patients) to characterize total and free plasma concentrations of erdafitinib following single- and multiple-dose administration, to understand clinically relevant covariates, and to quantify the inter- and intraindividual variability in erdafitinib PK. An open, linear, 3-compartment disposition model with first-order absorption and a lag time was used to describe the PK profile of total and free erdafitinib plasma concentrations. The PK of erdafitinib were linear and time independent. After oral administration, erdafitinib was rapidly absorbed, with a time to maximum concentration between 2 and 4 hours. In patients, erdafitinib total apparent oral clearance was 0.200 L/h (median free fraction = 0.24%), and the effective terminal half-life of total drug was 76.4 hours. Interindividual variability in PK parameters was moderate for oral clearance and central volume of distribution, and large for absorption rate and peripheral volume of distribution. Sex and renal function were significant covariates on free oral clearance, while weight, sex, and α1 -acid-glycoprotein were significant on oral central volume of distribution. Age, race, and mild hepatic impairment were not significant covariates of erdafitinib exposure. Given that the magnitude of the covariate effects were within 25% of reference values and that the recommended dosing regimen of erdafitinib comprises individual dose up-titrations and reductions based on presence or absence of toxicities, the clinical relevance of the investigated covariates is expected to be limited, and no dose adjustments are warranted. © 2019, The American College of Clinical Pharmacology.

Report this publication

Statistics

Seen <100 times